Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05748834 · ClinicalTrials.gov registry record · Phase 2
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by SCRI Development Innovations.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 8
- Study locations
NCT05748834 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by SCRI Development Innovations. The registered enrollment target is 36 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT05748834, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by SCRI Development Innovations.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 8
- Study locations
Study Summary
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Conditions Studied
Interventions
- DRUG Tucatinib
- DRUG Doxil
Study Locations (8)
Tennessee
- SCRI Oncology Partners - Nashville
- Tennessee Oncology - Nashville
Texas
- Texas Oncology- DFW - Dallas
- Texas Oncology- San Antonio - San Antonio
Virginia
- Virginia Oncology Associates - Norfolk
- Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc) - Salem
Maryland
- Maryland Oncology Hematology - Columbia
Pennsylvania
- Alliance Cancer Specialists - Bensalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05748834
The ClinicalTrials.gov registry entry for NCT05748834 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tucatinib is the first listed.
NCT05748834 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Tennessee, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT05748834 about?
NCT05748834 is a clinical study titled "Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer". This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more a...
What is the current status of trial NCT05748834?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-07-24. Estimated completion is 2027-11.
What conditions does trial NCT05748834 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05748834?
The interventions under investigation include: Tucatinib (DRUG), Doxil (DRUG).
Who is sponsoring clinical trial NCT05748834?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05748834 being conducted?
This trial has 8 study locations across Maryland, Pennsylvania, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.